The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma

Clin Nucl Med. 2015 Jan;40(1):47-9. doi: 10.1097/RLU.0000000000000589.

Abstract

A 68-year-old man, with a history of pituitary surgery and radiation therapy for pituitary macroadenoma 20 years earlier, presented with a pituitary mass and enlarging lesions within the posterior fossa and spinal canal. Biopsy revealed low-grade pituitary carcinoma. PET/CT scan showed multiple foci of increased Ga DOTATATE activity including pituitary and posterior fossa lesions. After 3 fractions of Lu DOTATATE therapy, the tumor remained stable over 4 years on MRI and Ga DOTATATE scans. This case illustrates the benefit of Ga DOTATATE PET/CT in malignant pituitary disease to assess potential for somatostatin receptor therapy with Lu DOTATATE and monitor treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Carcinoma / diagnostic imaging*
  • Carcinoma / radiotherapy
  • Humans
  • Male
  • Multimodal Imaging
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Pituitary Neoplasms / diagnostic imaging*
  • Pituitary Neoplasms / radiotherapy
  • Positron-Emission Tomography
  • Radiopharmaceuticals* / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Organometallic Compounds
  • Radiopharmaceuticals
  • gallium Ga 68 dotatate
  • lutetium Lu 177 dotatate
  • Octreotide